https://orcid.org/0000-0003-0304-9881
Figures
Abstract
Objectives
One primary concern about receiving care at home is that survival might be shortened because the quality and quantity of treatment provided at home will be inferior to that given in the hospital. Although our previous study demonstrated a longer survival of those with home-based palliative care (PC), it lacked adjustment for some potential confounders including symptoms and treatments during the stay. We aimed to compare the survival times among advanced cancer patients receiving home-based and hospital-based PC with adjusting for symptoms and treatments.
Method
We compared survival time of participants who enrolled two multicenter, prospective cohort studies of advanced cancer patients at 45-home-based PC services between July 2017 and December 2017, and at 23-hospital-based PC services between January 2017 and December 2017. We analyzed with stratification by the estimated survival of Days, Weeks, and Months, which were defined by modified Prognosis in Palliative care Study predictor models-A. We conducted a Cox regression analysis with adjusting for potential confounders including symptoms and treatments during the stay.
Results
A total of 2,998 patients were enrolled in both studies and 2,878 patients were analyzed; 988 patients receiving home-based PC and 1,890 receiving hospital-based PC. The survival time of patients receiving home-based PC was significantly longer than that of patients receiving hospital-based PC for the Days Prognosis (estimated median survival time: 10 days [95% CI 8.1–11.8] vs. 9 days [95% CI 8.3–10.4], p = 0.157), the Weeks prognosis (32 days [95% CI 28.9–35.4] vs. 22 days [95% CI 20.3–22.9], p < 0.001), and the Months Prognosis, (65 days [95% CI 58.2–73.2] vs. 32 days [95% CI 28.9–35.4], p < 0.001).
Citation: Hamano J, Takeuchi A, Mori M, Saitou Y, Yamaguchi T, Miyata N, et al. (2023) Comparison of survival times of advanced cancer patients with palliative care at home and in hospital. PLoS ONE 18(4): e0284147. https://doi.org/10.1371/journal.pone.0284147
Editor: Kenji Fujiwara, Kimura Hoospital, JAPAN
Received: October 28, 2022; Accepted: March 27, 2023; Published: April 13, 2023
Copyright: © 2023 Hamano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data cannot be shared publicly because of ethical aspects. For more information please contact the IRB of both studies. EASED study: mk-rinri@sis.seirei.or.jp Come Home study: sien.ningenss@un.tsukuba.ac.jp.
Funding: Funding Source This EASED study was supported in part by a Grant-in-Aid from the Japanese Hospice Palliative Care Foundation. This COME Home study was supported in part by JSPS KAKENHI Grant Number 19K10551 and 22H03305. The sponsor played no role in the study design, collection, analysis, or interpretation of the data, writing of the report, or in the decision to submit the paper for publication.
Competing interests: None of the authors have any financial or personal relationships to declare.
Introduction
Receiving care and dying in one’s preferred place is an essential factor for a high quality of death and dying [1,2]. More than half of all people would prefer to be cared for and die at home, and the quality of death and dying are actually superior at home than in hospital [3–6]. Previous studies indicated greater pain intensity and non-home death preference predicted hospital death [7] and 68% of bereaved families in Japan preferred for the patient to die at home [8]. A qualitative study in Norway revealed that the preference to die at home was stable over time and did not change with deterioration in health status and progression in illness [9]. However, receiving care at home may be achieved only at a very late disease stage or death at home may not be achieved for multiple reasons such as insufficient health care resources, lack of caregivers, and unpreparedness of the patient and family [4,10]. One of major concern is that the quality and quantity of medical treatment provided at home will be inferior to that given in hospital and that survival might be shortened [11–13].
A small retrospective study revealed that cancer patients receiving home-based palliative care had significantly longer survival times than those in hospital, though it was lacked of adjustment for sufficient prognostic factors and was conducted at a single center with a small number of patients [14].
Then we conducted the secondary analysis of a multicenter, prospective cohort study which demonstrated that cancer patients who died receiving home-based palliative care had similar or longer survival times than cancer patients who died in hospital with specialized palliative care. However, our study did not adjust for symptom severity and medical treatments during care that would influence survival [15], whether the survival time is actually different according to the type of palliative care remains unclear. In addition, the evidence of the difference in medical treatment between palliative care at home and in hospital, which might be used to interpret the difference of survival times, is lacking. Thus, we thought it is needed to explore the difference of the survival time between advanced cancer patients receiving home-based palliative care and hospital-based palliative care with considering the symptom severity and medical treatments during care.
The present study mainly aimed to investigate the potential difference of the survival time between advanced cancer patients receiving home-based palliative care and hospital-based palliative care, adjusting not only for patient characteristics and prognostic factors, but also for symptoms and treatments.
Materials and methods
We conducted two multicenter, prospective cohort studies of advanced cancer patients who were receiving home-based palliative care (Come Home study) or hospital-based palliative care (EASED study) in Japan, to compare the difference in survival time. Both studies aimed to document and account for the symptoms and medical treatments experienced by advanced cancer patients at the end of life. We standardized survey items and assessment tools. The Come Home study was conducted at 45 home care services between July 2017 and December 2017, and the EASED study was conducted at 23 hospital-based palliative care centers between January 2017 and December 2017. The home-based palliative care is a part of standard clinical care in Japan.
The physician primarily responsible for each patient performed an evaluation and recorded all outcome measures on the day of enrolment, and followed the patient until death or six months after enrollment. The physician evaluated the patients at least once a day in hospital, and at least once a week, and often daily, at home. The evaluation period ended when home care ended for reasons other than death or patients were discharged from hospital alive within six months. The patients in hospital-based PC usually experience an outpatient clinic, admission to a hospital, discharge to community palliative care, and die in a hospital. Both studies were conducted in accordance with the ethical standards of the Declaration of Helsinki and the ethical guidelines for research presented by the Ministry of Health, Labour, and Welfare of Japan. The institutional review boards of all participating services approved this study and main institutional review boards (Come Home study: University of Tsukuba, EASED study: Seirei Mikatahara General Hospital) approved the use of existing EASED data for secondary analysis, and to combine the data for analysis. The authors did not access to information that could identify individual participants during or after data collection.
Patients
We enrolled eligible patients separately for both studies. The Come Home study enrolled patients when they started home-based palliative care, and the EASED study enrolled the patients when they started hospital-based palliative care at the participating facilities during the study period. The eligibility criteria for the two studies were the same; 1) 18 years old or older, 2) locally advanced or metastatic cancer (including hematopoietic neoplasms), and 3) started home-based or hospital-based palliative care at the participating facilities. Both studies excluded all patients who declined to participate in the study. Patients scheduled to be transferred or discharged within a week were excluded from receiving hospital-based palliative care.
Outcomes
The primary endpoint of this study was survival time of participants. Survival time was defined as the period from the day of enrolment to the date of death. To adjust for background factors with a potential influence on survival time, we obtained data on the day of enrolment to formulate modified Prognosis in Palliative care Study predictor models-A (PiPs-A) [16], and data to formulate the Age-adjusted Charlson Comorbidity Index (ACCI) [17] which includes age and comorbidities. The modified PiPS-A includes the following: site of primary cancer, metastatic site, Abbreviated Mental Test score by physician rating, heart rate, anorexia, dyspnea, dysphasia, fatigue, weight loss in the previous month, Eastern Cooperative Oncology Group performance status, and global health status (rated on a specific 7-point scale used in the original study: [1] extremely poor health to [7] normal health). Symptoms were recorded as being either present or absent. Cognitive status was evaluated according to the Abbreviated Mental Test score used in the original Prognosis in Palliative Care Study models, as reported by Gwilliam et al [18]. In the current study, cognitive status was rated as absent if the score on the Abbreviated Mental Test was 4 points or more, and as present if the score was less than 3 (scoring was performed by a physician without interviewing the patient).
We also obtained data on the day of enrolment to formulate the Palliative Prognostic Index (PPI) [19] as a covariate factor of survival time. The PPI includes the following; Palliative Performance Scale (categorized into three groups: 10–20, 30–50, and 60 or more), oral intake (categorized as severely reduced, moderately reduced, or absent), edema (categorized as present or absent), dyspnea at rest (present or absent), and delirium defined by Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) (present or absent).
We recorded several other symptoms and medical treatment factors associated with survival time based on the previous study and discussion among the researchers [20–24].
The symptoms on the day of enrolment, including pleural effusion (categorized as present or absent), asities (present or absent), bowel obstruction (present or absent), and hyperactive delirium defined by Memorial Delirium Assessment Scale item 9 (MDAS#9) [25] (present or absent) were recorded along with the symptom severity defined by the Integrated Palliative Care Outcome Scale (IPOS) and scored as 0 (not at all), 1 (slight), 2 (moderate), 3 (severe), or 4 (overwhelming), and the prevalence for any IPOS symptoms scored as 2, 3 or 4 [26,27]. We also recorded the symptoms during the enrolled periods; delirium defined by DSM-5, hyperactive delirium defined by MDAS#9, and the symptom severity at one week, three days, and one day before death (i.e., weakness or lack of energy at three days before death).
Medical treatment at the day of enrolment, such as chemotherapy within a month, use of oxygen therapy, use of any catheter, opioid dosage, and use of antipsychotic drugs, was recorded. Similarly, we recorded the medical treatment during the enrolled periods; use of antipsychotic drugs, palliative sedation, and medical treatment before death (i.e., dosage of opioids at one week before death and parenteral hydration during the 24 hours before death).
Statistical analysis
We excluded patients whose date of death was missing, but we did not exclude or separate patients who moved from one setting to another. We conducted our analyses on complete-cases and then applied multivariate multiple imputations by chained equations (MICE) with patients having missing data before death, namely patients who moved from home to other settings, to compare survival times.
We performed MICE 10 times for the variables on the day of enrolment, i.e., use of oxygen therapy, three categories of modified PiPs-A, PPI≥6.5, presence of delirium, presence of hyperactive delirium, IPOS of dyspnea, fatigue, bowel obstruction, and for the variables during the enrolled periods, i.e., presence of delirium, presence of hyperactive delirium, palliative sedation, and use of antibiotics during the 24 hours before death. We also confirmed beforehand that the distribution and proportions of the variables on the day of enrolment did not change between subjects who were supplemented by MICE and those who were not.
To explore the difference in survival times among patients with similar background factors having a potential influence on survival time, we selected a set of confounders between the settings of PC (receiving home-based PC or hospital-based PC) and outcome (survival from the day of enrollment) based on several previous studies and clinical knowledge [20–24]. Subsequently, we compared survival times for the following modified PiPS-A survival groups: patients surviving for Days (0–13 days), Weeks (14–55 days), and Months (>55 days), based on our previous study [15]. We plotted survival curves with the Kaplan-Meier method and compared the survival times of patients who were receiving home-based palliative care and hospital-based palliative care. In addition, we conducted a Cox regression analysis to estimate the adjusted hazard ratio (HR) for survival of patients receiving home-based versus hospital-based PC by adjusting the confounders. We defined the confounders based on previous studies and discussion among the authors [19,28–33]; age (per decade), sex, primary cancer site, presence of metastasis, chemotherapy within a month, PiPs-A, PPI (≥6.5), ACCI (≥6), hyperactive delirium, use of oxygen therapy, use of any catheter, and symptoms and treatment at enrollment and during care. We defined the cutoffs of opioid dosage as greater than or equal to 120 mg/day based on a previous study that explored whether opioids influenced survival among advanced cancer patients [33].
We conducted sensitivity analyses using propensity score matching for patients’ background data of home-based and hospital-based PC to assess how substantial the effect of missing (unknown) confounders masked a true HR about the confounders of survival time. Differences in variable distributions between home-based PC and hospital-based PC were compared using Student’s t test for continuous variables and Pearson’s χ2 test or Fisher’s exact test for categorical variables. Significance was accepted at P < .05 and analyses were conducted using SPSS-J software (version 25.0; IBM, Tokyo, Japan) and SAS 9.4 (Cary, NC, USA).
Results
In total, 2,998 patients were enrolled in both studies; 1,102 patients receiving home-based palliative care and 1,896 patients receiving hospital-based palliative care. Among them, 120 patients (home-based: 114, hospital-based:6) were excluded because the date of death was missing. Subsequently, 2,878 patients were analyzed; 988 patients receiving home-based palliative care and 1,890 patients receiving hospital-based palliative care (S1 Appendix).
The mean age was 72.5 years (95% CI: 72.1–73.0). The gastrointestinal tract/ hepatobiliary system and pancreas were the most frequent sites of primary cancer, followed by lung cancer. Almost one-third of patients had PPI ≥ 6.5, and approximately half were predicted to have a weekly prognosis by modified PiPS-A. The mean survival time was 35.2 days (95% CI: 33.6–36.7) for all patients; 51.0 days (95% CI: 47.5–54.4) for patients receiving home-based palliative care and 26.9 days (95% CI: 25.6–28.3) for patients receiving hospital-based palliative care (Table 1).
Symptoms and treatment until death
Table 2 shows the prevalence of symptoms and treatment until death. The patients with hospital-based palliative care had significantly poorer performance status health and higher symptom prevalence than patients in home-based palliative care, except for drowsiness, sore or dry mouth, hyperactive delirium at three days before death, and ascites.
Comparison of survival time between home-based palliative care and hospital-based palliative care
The survival of patients receiving home-based palliative care was significantly longer than that of those receiving hospital-based palliative care for the Weeks prognosis group (estimated median survival time: 32 days [95% CI 28.9–35.4] vs. 22 days [95% CI 20.3–22.9], p<0.001) and the Months prognosis group (65 days [95% CI 58.2–73.2] vs. 32 days [95% CI 28.9–35.4], p<0.001), as defined by PiPs-A. No significant difference was identified in the Days prognosis group (10 days [95% CI 8.1–11.8] vs. 9 days [95% CI 8.3–10.4], p = 0.157) (Fig 1).
Cox proportional hazards analysis revealed that home-based palliative care had a significant positive influence on survival time in both the unadjusted (HR, 0.70 [95% CI, 0.64–0.77]; P< 0.001) and adjusted models with patients’ background, symptoms, and treatment (at enrollment, during care, at 1 week before death), symptoms at 3 days before death, and treatment at last day before death (HR, 0.82 [95% CI, 0.71–0.95]; P = 0.007). High-dose opioids (oral morphine equivalent ≥ 120 mg) at one week before death had a significant positive influence on survival time, although that treatment at enrollment had a significant negative influence and that on the last day before death had no significant influence on survival time. Parental hydration at one week before death had a significant positive influence, whereas that on the last day before death had a significant negative influence (Table 3).
Discussion
To the best of our knowledge, this is the first large-scale prospective, multicenter study to compare the survival time of advanced cancer patients receiving home-based palliative care or hospital-based palliative care adjusting for symptoms and treatment factors.
The most important finding of this study is that advanced cancer patients receiving home-based palliative care with an estimated Weeks or Months prognosis survived longer than those receiving hospital-based PC, whereas those with an estimated Days prognosis survived similar times receiving hospital-based palliative care after adjusting for symptoms and treatments. Our previous multicenter study suggested that cancer patients who died receiving home-based palliative care had similar or significantly longer survival times than those who died in hospital with specialized palliative care services, although that study lacked adjustment for symptoms and medical treatment. As several previous studies demonstrated that symptoms and treatment are associated with the survival time of advanced cancer patients [34–37], our current study was novel to present that advanced cancer patients receiving home-based palliative care with an estimated Weeks or Months prognosis survived longer than those receiving hospital-based palliative care by adjusting for symptoms and treatment factors.
One possible hypothesis that estimated Weeks or Months prognosis survived longer than those receiving hospital-based palliative care might be due to the difference in the living environment. In other words, the inpatient environment may interfere with the patient’s autonomy and motivation, which in turn may negatively affect activities, appetite, and other matters necessary for survival. Another possible hypothesis that an estimated Days prognosis had similar survival times was the physiological effects of the dying process prevail over the type of specialist palliative care. This explanation would reflect the concept of palliative care; palliative care intends neither to hasten or postpone death and focus on relief from pain and other distressing symptoms. This result implied that distinguishing the Days prognosis is important to decide treatment and care plan.
Of note, our study did not indicate a clear association between the quality of symptom control or burden of suffering and survival time. However, previous studies demonstrated that symptoms are associated with the survival time of advanced cancer patients [34–37]. Therefore, one possible explanation was that our study could not reveal symptom control details with day-by-day assessment.
A strength of this study was the large sample size that used many adjustment variables based on multiple areas including patient characteristics, prognostic factors, symptoms, and medical treatments. Since it is ethically difficult to conduct RCT, our large-scale prospective, multicenter study with multifactorial adjustments would be the high level of evidence available [38]. Another strength of our study is that missing data caused by changes in the place of care were supplemented and analyzed with multivariate multiple imputations by chained equations.
The current study also had some limitations. First, we were unable to control the general condition of the two groups at enrollment. We thought survival time cannot be compared without aligning the general condition among two groups, and it is difficult to achieve a rigorous alignment of the general conditions, even with maximum adjustment of the various prognostic markers. Therefore, our result, advanced cancer patients with a Weeks or Months prognosis, those receiving home-based palliative care survived longer than those receiving hospital-based palliative care, could be due to their better general conditions at enrollment. However, since we adjusted for the validated prognostic scales, PiPS-A and PPI, we do not believe that there was an extremely large difference in the general condition of the two groups.
Second, we were unable to adjust for residual confounding factors affecting the choice of the type of palliative care and survival time such as the preferences of patients and their families, family support, the details of dose-response treatment, and spiritual well-being.
Third, we were unable to consider the interaction of successive symptoms and medical treatments in terms of time-dependent manner. Thus, further research is needed to clarify the potential effects of symptoms and medical treatments as time-dependent confounding factors on survival time.
Fourth, sometimes a patient at home could not be assessed on a defined date such as a week before death, three days before death, or the last day before death. It is therefore possible that some of the evaluations at home were based on physicians’ estimates, which may have caused under- or overestimation of symptoms for home-based palliative care patients. Nevertheless, we believe that our large-scale, prospective, multicenter study offers the highest available level of evidence and closely maps reality.
Fifth, we did not measure the number of patients with crossover between home and hospital parts of the study. While a high percentage of crossover may affect outcomes [39], we believe it did not seriously affect this study because very few of the facilities that participated in the two studies were located in the same area, and the study periods only partially overlapped.
Thus, we could not conclude a causal relationship or clarify the scientific mechanisms between the type of palliative of care and the survival time of advanced cancer patients in this observational study. Further observational studies based on causal inference are needed to uncover whether advanced cancer patients at home shorten their survival time compared to staying in the hospital [38]. Once this becomes clear, patients, families, and providers would feel more comfortable choosing home care if they knew that advanced cancer patients receiving home palliative care would not have a shorter survival time than those receiving inpatient palliative care.
Conclusions
In this cohort of advanced cancer patients receiving home-based palliative care with an estimated Weeks or Months prognosis survived longer than those receiving hospital-based PC, whereas those with an estimated Days prognosis survived similar times receiving hospital-based palliative care after adjusting for symptoms and treatments. Further studies are needed to clarify that the survival time of home patients is not shorter than that of inpatients.
Acknowledgments
This study was performed as part of the comparison of end-of-life trajectory in advanced cancer patients between home (Come Home study) and inpatient hospice (the East-Asian collaborative cross-cultural study to elucidate the dying process: EASED study).
The participating investigators and study sites of the Come Home study were as follows: Keijiro Miyake, M.D., Ph.D. (Keijiro Clinic), Manabu Tamura, M.D., Ph.D. (Osaka Home Healthcare Clinic), Junichiro Toya, M.D. (Sakura-shinmachi Urban Clinic), Hiroto Shirayama, M.D. (Osaka Kita Home Care Clinic), Takamichi Matsuki, M.D., Ph.D. (Fujisawa-Honmachi Family Clinic), Akihiro Ishikawa, M.D., (Ishikawa Rehabili Noushinkeigeka Clinic), Yasunori Muraoka, M.D. (Muraoka Home Clinic), Yasuhiro Saitou, M.D. (GP Clinic Jiyugaoka), Takahide Yamaguchi, M.D. (Yamaguchi Clinic), Tomohiro Nishi, M.D. (Kawasaki Municipal Ida Hospital), Nobuyuki Miyata, M.D. (Miyata Clinic), Masakatsu Shimizu, M.D., Ph.D. (Shimizu Medical Clinic), Ryo Yamamoto, M.D. (Saku Central Hospital Advanced Care Center), Yousuke Kimura, M.D. (Yamato Clinic), Yoshiyuki Kamiyama, M.D. (Okinawa Chubu Hospital), Yasuyuki Arai, M.D., Ph.D. (Iki-iki Clinic), Hiroshi Matsuo, M.D. (Margaret Clinic), Hideki Shishido, M.D. (Shishido Internal Medicine Clinic), Kazushi Nakano, M.D., Ph.D. (Nakano Zaitakuiryou Clinic), Kan Asahina, M.D. (Mutsumimachi Clinic), Maiko Haruki, M.D. (Orange Home-Care Clinic), Keiko Inoue, M.D. (Aisei Clinic), Sen Otomo, M.D., (Seimeikan Clinic).
The participating investigators and study sites in the EASED study were as follows: Satoshi Inoue, M.D. (Seirei Hospice, Seirei Mikatahara General Hospital), Naosuke Yokomichi, M.D., Ph.D. (Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital), Hiroaki Tsukuura, M.D., Ph.D. (Department of Palliative Care, TUMS Urayasu Hospital), Toshihiro Yamauchi, M.D. (Seirei Hospice, Seirei Mikatahara General Hospital), Akemi Shirado Naito, M.D. (Department of palliative care Miyazaki Medical Association Hospital), Yu Uneno, M.D. (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University), Akira Yoshioka, M.D., Ph.D. (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Shuji Hiramoto, M.D. (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Ayako Kikuchi, M.D. (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Tetsuo Hori, M.D. (Department of Respiratory surgery, Mitsubishi Kyoto Hospital), Yosuke Matsuda, M.D. (Palliative Care Department, St.Luke’s International Hospital), Hiroyuki Kohara, M.D., Ph.D. (Hiroshima Prefectural Hospital), Hiromi Funaki, M.D. (Hiroshima Prefectural Hospital), Keiko Tanaka, M.D., Ph.D. (Department of Palliative Care Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital), Kozue Suzuki, M.D. (Department of Palliative Care Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital), Tina Kamei, M.D. (Department of Palliative Care, NTT Medical Center Tokyo), Koji Amano, M.D. (Department of Palliative Medicine, Osaka City General Hospital), Teruaki Uno, M.D. (Department of Palliative Medicine, Osaka City General Hospital), Jiro Miyamoto, M.D. (Department of Palliative Medicine, Osaka City General Hospital), Hirofumi Katayama, M.D. (Department of Palliative Medicine, Osaka City General Hospital), Hideyuki Kashiwagi, M.D., MBA. (Aso Iizuka Hospital / Transitional and Palliative Care), Eri Matsumoto, M.D. (Aso Iizuka Hospital / Transitional and Palliative Care), Takeya Yamaguchi, M.D. (Japan Community Health care Organization Kyushu Hospital / Palliative Care), Tomonao Okamura, M.D., MBA. (Aso Iizuka Hospital / Transitional and Palliative Care), Hoshu Hashimoto, M.D., MBA. (Inoue Hospital / Internal Medicine), Shunsuke Kosugi, M.D. (Department of General Internal Medicine, Aso Iizuka Hospital), Nao Ikuta, M.D. (Department of Emergency Medicine, Osaka Red Cross Hospital), Yaichiro Matsumoto, M.D. (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Takashi Ohmori, M.D. (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Takehiro Nakai, M.D. (Immuno-Rheumatology Center, St Luke’s International Hospital), Takashi Ikee, M.D. (Department of Cardiology, Aso Iizuka Hospital), Yuto Unoki, M.D. (Department of General Internal Medicine, Aso Iizuka Hospital), Kazuki Kitade, M.D. (Department of Orthopedic Surgery, Saga-Ken Medical Centre Koseikan), Shu Koito, M.D. (Department of General Internal Medicine, Aso Iizuka Hospital), Nanao Ishibashi, M.D. (Environmental Health and Safety Division, Environmental Health Department, Ministry of the Environment), Masaya Ehara, M.D. (TOSHIBA), Kosuke Kuwahara, M.D. (Department of General Internal Medicine, Aso Iizuka Hospital), Shohei Ueno, M.D. (Department of Hematology / Oncology, Japan Community Healthcare Organization Kyushu Hospital), Shunsuke Nakashima, M.D. (Oshima Clinic), Yuta Ishiyama, M.D. (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Akihiro Sakashita, M.D., Ph.D. (Department of Palliative Medicine, Kobe University School of Medicine), Hana Takatsu, M.D. (Division of Palliative Care, Konan Medical Center), Takashi Yamaguchi, M.D., Ph.D. (Division of Palliative Care, Konan Medical Center), Satoko Ito, M.D. (Hospice, The Japan Baptist Hospital), Toru Terabayashi, M.D. (Hospice, The Japan Baptist Hospital), Jun Nakagawa, M.D. (Hospice, The Japan Baptist Hospital), Tetsuya Yamagiwa, M.D., Ph.D. (Hospice, The Japan Baptist Hospital), Akira Inoue, M.D., Ph.D. (Department of Palliative Medicine Tohoku University School of Medicine), Takuhiro Yamaguchi, Ph.D. (Professor of Biostatistics, Tohoku University Graduate School of Medicine), Mitsunori Miyashita, R.N., Ph.D. (Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine), Saran Yoshida, Ph.D. (Graduate School of Education, Tohoku University), Yusuke Hiratsuka, M.D., Ph.D. (Department of Palliative Medicine Tohoku University School of Medicine), Keita Tagami, M.D., Ph.D. (Department of Palliative Medicine Tohoku University School of Medicine), Hiroaki Watanabe, M.D. (Department of Palliative Care, Komaki City Hospital), Takuya Odagiri, M.D. (Department of Palliative Care, Komaki City Hospital), Tetsuya Ito, M.D.,Ph.D. (Department of Palliative Care, Japanese Red Cross Medical Center), Masayuki Ikenaga, M.D. (Hospice, Yodogawa Christian Hospital), Keiji Shimizu, M.D., Ph.D. (Department of Palliative Care Internal Medicine, Osaka General Hospital of West Japan Railway Company), Akira Hayakawa, M.D., Ph.D. (Hospice, Yodogawa Christian Hospital), Rena Kamura, M.D. (Hospice, Yodogawa Christian Hospital), Takeru Okoshi, M.D., Ph.D. (Okoshi Nagominomori Clinic), Isseki Maeda M.D., Ph.D. (Department of Palliative Care, Senri-Chuo Hospital), Tomohiro Nishi, M.D. (Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center), Kazuhiro Kosugi, M.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Yasuhiro Shibata, M.D. (Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center), Takayuki Hisanaga, M.D. (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Takahiro Higashibata, M.D., Ph.D. (Department of General Medicine and Primary Care, Palliative Care Team, University of Tsukuba Hospital), Ritsuko Yabuki, M.D. (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Shingo Hagiwara, M.D., Ph.D. (Department of Palliative Medicine, Yuai Memorial Hospital), Miho Shimokawa, M.D. (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Satoshi Miyake, M.D., Ph.D. (Professor, Department of Clinical Oncology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University (TMDU)), Junko Nozato, M.D. (Specially Appointed Assistant Professor, Department of Internal Medicine, Palliative Care, Medical Hospital, Tokyo Medical and Dental University), Hiroto Ishiki, M.D. (Department of Palliative Medicine, National Cancer Center Hospital), Tetsuji Iriyama, M.D. (Specially Appointed Assistant Professor, Department of Internal Medicine, Palliative Care, Medical Hospital, Tokyo Medical and Dental University), Keisuke Kaneishi, M.D., Ph.D. (Department of Palliative Care Unit, JCHO Tokyo Shinjuku Medical Center), Tomofumi Miura, M.D., Ph.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Yoshihisa Matsumoto, M.D., Ph.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Ayumi Okizaki, Ph.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Yuki Sumazaki Watanabe, M.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Yuko Uehara, M.D. (Department of Palliative Medicine, National Cancer Center Hospital East), Eriko Satomi, M.D. (Department of Palliative Medicine, National Cancer Center Hospital), Kaoru Nishijima, M.D. (Department of Palliative Medicine, Kobe University Graduate School of Medicine), Junichi Shimoinaba, M.D. (Department of Hospice Palliative Care, Eikoh Hospital), Ryoichi Nakahori, M.D. (Department of Palliative Care, Fukuoka Minato Home Medical Care Clinic), Takeshi Hirohashi, M.D. (Eiju General Hospital), Jun Hamano, M.D., Ph.D. (Assistant Professor, Faculty of Medicine, University of Tsukuba), Natsuki Kawashima, M.D. (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Takashi Kawaguchi, Ph.D. (Tokyo University of Pharmacy and Life Sciences Department of Practical Pharmacy), Megumi Uchida, M.D., Ph.D. (Dept. of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences), Ko Sato, M.D., Ph.D. (Hospice, Ise Municipal General Hospital), Yoichi Matsuda, M.D., Ph.D. (Department of Anesthesiology & Intensive Care Medicine / Osaka University Graduate School of Medicine), Yutaka Hatano, M.D., Ph.D. (Hospice, Gratia Hospital), Satoru Tsuneto, M.D., Ph.D. (Professor, Department of Human Health Sciences, Graduate School of Medicine, Kyoto University Department of Palliative Medicine, Kyoto University Hospital), Sayaka Maeda, M.D. (Department of Palliative Medicine, Kyoto University Hospital), Yoshiyuki Kizawa M.D., Ph.D., FJSIM, DSBPMJ. (Designated Professor and Chair, Department of Palliative Medicine, Kobe University School of Medicine), Hiroyuki Otani, M.D. (Palliative Care Team, and Palliative and Supportive Care, National Kyushu Cancer Center).
References
- 1. Hirai K, Miyashita M, Morita T, Sanjo M, Uchitomi Y. Good death in Japanese cancer care: a qualitative study. J Pain Symptom Manage. 2006;31: 140–7. pmid:16488347
- 2. Miyashita M, Sanjo M, Morita T, Hirai K, Uchitomi Y. Good death in cancer care: a nationwide quantitative study. Ann Oncol Off J Eur Soc Med Oncol. 2007;18: 1090–7. pmid:17355953
- 3. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers’ mental health. J Clin Oncol. 2010;28: 4457–64. pmid:20837950
- 4. Higginson IJ, Sen-Gupta GJA. Place of care in advanced cancer: A qualitative systematic literature review of patient preferences. J Palliat Med. 2000;3: 287–300. pmid:15859670
- 5. Gomes B, Calanzani N, Gysels M, Hall S, Higginson IJ. Heterogeneity and changes in preferences for dying at home: A systematic review. BMC Palliative Care. BMC Palliat Care; 2013. pmid:23414145
- 6. Teno JM, Clarridge BR, Casey V, Welch LC, Wetle T, Shield R, et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004;291: 88–93. pmid:14709580
- 7. Tay RY, Choo RWK, Ong WY, Hum AYM. Predictors of the final place of care of patients with advanced cancer receiving integrated home-based palliative care: a retrospective cohort study. BMC Palliat Care. 2021;20. pmid:34663303
- 8. Choi JE, Miyashita M, Hirai K, Sato K, Morita T, Tsuneto S, et al. Preference of place for end-of-life cancer care and death among bereaved Japanese families who experienced home hospice care and death of a loved one. Support Care Cancer. 2010;18: 1445–1453. pmid:19859745
- 9. Nysæter TM, Olsson C, Sandsdalen T, Wilde-Larsson B, Hov R, Larsson M. Preferences for home care to enable home death among adult patients with cancer in late palliative phase—a grounded theory study. BMC Palliat Care. 2022;21: 49. pmid:35410199
- 10. Gomes B, Calanzani N, Gysels M, Hall S, Higginson IJ. Heterogeneity and changes in preferences for dying at home: a systematic review. BMC Palliat Care. 2013;12: 7. pmid:23414145
- 11. Sato K, Miyashita M, Morita T, Suzuki M. The Japanese perception of feasibility of end-of-life home care until death and related factors. Palliat Care Res. 2007;2: 101–111.
- 12. Seymour J, Payne S, Chapman A, Holloway M. Hospice or home? Expectations of end-of-life care among white and Chinese older people in the UK. Sociol Health Illn. 2007;29: 872–890. pmid:17986020
- 13. Miyashita M, Arai K, Yamada Y, Owada M, Sasahara T, Kawa M, et al. Discharge from a Palliative Care Unit: Prevalence and Related Factors from a Retrospective Study in Japan. J Palliat Med. 2009;12: 142–149. pmid:19207057
- 14. Murakami N, Tanabe K, Morita T, Kadoya S, Shimada M, Ishiguro K, et al. Going back to home to die: does it make a difference to patient survival? BMC Palliat Care. 2015;14: 7. pmid:25821408
- 15. Hamano J, Yamaguchi T, Maeda I, Suga A, Hisanaga T, Ishihara T, et al. Multicenter cohort study on the survival time of cancer patients dying at home or in a hospital: Does place matter? Cancer. 2016;122: 1453–1460. pmid:27018875
- 16. Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T, et al. Independent Validation of the Modified Prognosis Palliative Care Study (PiPS) Predictor Models in Three Palliative Care Settings. J Pain Symptom Manage. 2015;5: 853–860. pmid:25499420
- 17. Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112: 2384–92. pmid:18404699
- 18. Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, et al. Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ. 2011;343: d4920. Available: http://www.ncbi.nlm.nih.gov/pubmed/21868477. pmid:21868477
- 19. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer. 1999/05/21. 1999;7: 128–133. Available: http://www.ncbi.nlm.nih.gov/pubmed/10335930. pmid:10335930
- 20. Allard P, Dionne A, Potvin D. Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care. 1995;11: 20–24. pmid:7472787
- 21. Chang JA, Lin CC. A longitudinal study of the role of patient-reported outcomes on survival prediction of palliative cancer inpatients in Taiwan. Support Care Cancer. 2009;17: 1285–1294. pmid:19214595
- 22. Just J, Schmitz M-T, Grabenhorst U, Joist T, Horn K, Engel B, et al. Factors influencing length of survival in ambulatory palliative care—a cross sectional study based on secondary data. BMC Palliat Care. 2021;20. pmid:34001099
- 23. Tsai JS, Chen CH, Wu CH, Chiu TY, Morita T, Chang CH, et al. Consciousness levels one week after admission to a palliative care unit improve survival prediction in advanced cancer patients. J Palliat Med. 2015;18: 170–175. pmid:25191971
- 24. Kim AS, Youn CH, Ko HJ, Kim HM. The survival time of terminal cancer patients: Prediction based on clinical parameters and simple prognostic scores. J Palliat Care. 2014;30: 24–31. pmid:24826440
- 25. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13: 128–37. pmid:9114631
- 26. Sakurai H, Miyashita M, Imai K, Miyamoto S, Otani H, Oishi A, et al. Validation of the Integrated Palliative care Outcome Scale (IPOS)—Japanese Version. Jpn J Clin Oncol. 2019;49: 257–262. pmid:30668720
- 27. Schildmann EK, Groeneveld EI, Denzel J, Brown A, Bernhardt F, Bailey K, et al. Discovering the hidden benefits of cognitive interviewing in two languages: The first phase of a validation study of the Integrated Palliative care Outcome Scale. Palliat Med. 2016;30: 599–610. pmid:26415736
- 28. Gomes B, Calanzani N, Koffman J, Higginson IJ. Is dying in hospital better than home in incurable cancer and what factors influence this? A population-based study. BMC Med. 2015;13: 235. pmid:26449231
- 29. Gomes B, Higginson IJ. Factors influencing death at home in terminally ill patients with cancer: systematic review. BMJ. 2006;332: 515–21. pmid:16467346
- 30. Wu C-C, Hsu T-W, Chang C-M, Yu C-H, Lee C-C. Age-Adjusted Charlson Comorbidity Index Scores as Predictor of Survival in Colorectal Cancer Patients Who Underwent Surgical Resection and Chemoradiation. Medicine (Baltimore). 2015;94: e431. pmid:25590852
- 31. Tian Y, Jian Z, Xu B, Liu H. Age-adjusted Charlson comorbidity index score as predictor of survival of patients with digestive system cancer who have undergone surgical resection. Oncotarget. 2017;8: 79453–79461. pmid:29108324
- 32. Murtagh FE, Ramsenthaler C, Firth A, Groeneveld EI, Lovell N, Simon ST, et al. A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS). Palliat Med. 2019;33: 1045–1057. pmid:31185804
- 33. Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J. Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc. 2011;12: 129–34. pmid:21266289
- 34. Park SJ, Ahn HK, Ahn HY, Han KT, Hwang IC. Association between continuous deep sedation and survival time in terminally ill cancer patients. Support Care Cancer. 2021;29: 525–531. pmid:32415383
- 35. Tsai JS, Wu CH, Chiu TY, Chen CY. Significance of Symptom Clustering in Palliative Care of Advanced Cancer Patients. J Pain Symptom Manage. 2010;39: 655–662. pmid:20226623
- 36. Narducci F, Grande R, Mentuccia L, Trapasso T, Sperduti I, Magnolfi E, et al. Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: A pilot study. Support Care Cancer. 2012;20: 1221–1226. pmid:21688165
- 37. Barata PC, Cardoso A, Custodio MP, Alves M, Papoila AL, António B, et al. Symptom clusters and survival in Portuguese patients with advanced cancer. Cancer Med. 2016;5: 2731–2739. pmid:27624994
- 38. Hernán MA. Methods of Public Health Research—Strengthening Causal Inference from Observational Data. N Engl J Med. 2021;385: 1345–1348. pmid:34596980
- 39. Wang NC. Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation. JAMA. 2019;322: 1105–1106. pmid:31529001